{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:19:30Z","timestamp":1789924770707,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurophysiology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clinph.2014.06.031","type":"journal-article","created":{"date-parts":[[2014,7,4]],"date-time":"2014-07-04T11:31:24Z","timestamp":1404473484000},"page":"2328-2336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Lambert\u2013Eaton myasthenic syndrome \u2013 Diagnosis, pathogenesis and therapy"],"prefix":"10.1016","volume":"125","author":[{"given":"Robert","family":"H\u00fclsbrink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Hashemolhosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinph.2014.06.031_b0005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.1139","article-title":"Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert\u2013Eaton myasthenic syndrome: summary statement","volume":"24","author":"AAEM Quality Assurance Committee","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2014.06.031_b0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2249.1990.tb05440.x","article-title":"Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin","volume":"82","author":"Aarli","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/00365599509180590","article-title":"Adenocarcinoma of the prostate and Eaton\u2013Lambert syndrome. A previously unreported association","volume":"29","author":"Agarawal","year":"1995","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.clinph.2014.06.031_b0020","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(53)91358-0","article-title":"Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine","volume":"265","author":"Anderson","year":"1953","journal-title":"Lancet"},{"key":"10.1016\/j.clinph.2014.06.031_b0025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/clinchem\/41.4.537","article-title":"Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31\u201398) as tumor marker for small-cell lung carcinoma: development and evaluation","volume":"41","author":"Aoyagi","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinph.2014.06.031_b0030","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0165-5728(00)00431-8","article-title":"Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line","volume":"113","author":"Benatar","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0040","first-page":"214","article-title":"Piccolo, a novel 420kDa protein associated with the presynaptic cytomatrix","volume":"69","author":"Cases-Langhoff","year":"1996","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.clinph.2014.06.031_b0045","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Response of the Lambert\u2013Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0050","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1523\/JNEUROSCI.3771-10.2011","article-title":"Calcium channels link the muscle-derived synapse organizer laminin beta2 to Bassoon and CAST\/Erc2 to organize presynaptic active zones","volume":"31","author":"Chen","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinph.2014.06.031_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0140-6736(93)92485-C","article-title":"Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies","volume":"341","author":"Darnell","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.clinph.2014.06.031_b0060","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1113\/jphysiol.1954.sp005129","article-title":"Quantal components of the end-plate potential","volume":"124","author":"Del Castillo","year":"1954","journal-title":"J Physiol"},{"key":"10.1016\/j.clinph.2014.06.031_b0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1083\/jcb.142.2.499","article-title":"Bassoon, a novel zinc-finger CAG\/glutamine-repeat protein selectively localized at the active zone of presynaptic nerve terminals","volume":"142","author":"Tom Dieck","year":"1998","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clinph.2014.06.031_b0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10072-014-1637-4","article-title":"Italian recommendations for Lambert\u2013Eaton myasthenic syndrome (LEMS) management","volume":"35","author":"Evoli","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0080","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2010.10.003","article-title":"Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P\/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies","volume":"21","author":"Fernandez-Torron","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinph.2014.06.031_b0085","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/mus.880050905","article-title":"Paucity and disorganization of presynaptic membrane active zones in the Lambert\u2013Eaton myasthenic syndrome","volume":"5","author":"Fukunaga","year":"1982","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2014.06.031_b0090","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1073\/pnas.80.24.7636","article-title":"Passive transfer of Lambert\u2013Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones","volume":"80","author":"Fukunaga","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinph.2014.06.031_b0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S0317167100002729","article-title":"Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer","volume":"30","author":"Gill","year":"2003","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0100","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0110","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.1997.15.8.2866","article-title":"Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival","volume":"15","author":"Graus","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinph.2014.06.031_b0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/jb\/mvq065","article-title":"CAST and ELKS proteins: structural and functional determinants of the presynaptic active zone","volume":"148","author":"Hida","year":"2010","journal-title":"J Biochem"},{"key":"10.1016\/j.clinph.2014.06.031_b0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.clinph.2014.06.031_b0130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.humimm.2013.03.004","article-title":"Antibodies to active zone protein ERC1 in Lambert\u2013Eaton myasthenic syndrome","volume":"74","author":"Huijbers","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0135","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(05)67569-1","article-title":"Small-cell lung cancer","volume":"366","author":"Jackman","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinph.2014.06.031_b0140","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/annonc\/mdr303","article-title":"Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients >80","volume":"23","author":"Janssen-Heijnen","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinph.2014.06.031_b0145","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/j.1460-9568.2007.05438.x","article-title":"Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya","volume":"25","author":"Kaja","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.clinph.2014.06.031_b0150","article-title":"Treatment for Lambert\u2013Eaton myasthenic syndrome","volume":"2","author":"Keogh","year":"2011"},{"key":"10.1016\/j.clinph.2014.06.031_b0155","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinph.2014.06.031_b0160","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0006-3495(78)85503-9","article-title":"3,4-Diaminopyridine. A potent new potassium channel blocker","volume":"22","author":"Kirsch","year":"1978","journal-title":"Biophys J"},{"key":"10.1016\/j.clinph.2014.06.031_b0165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0022-510X(99)00125-2","article-title":"Calcium channel peptide can cause an autoimmune-mediated model of Lambert\u2013Eaton myasthenic syndrome in rats","volume":"166","author":"Komai","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0170","first-page":"612","article-title":"Defect of neuromuscular conduction associated with malignant neoplasms","volume":"187","author":"Lambert","year":"1956","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinph.2014.06.031_b0175","first-page":"32","article-title":"Large granular lymphocytic leukemia associated with Lambert\u2013Eaton myasthenic syndrome: a case report","volume":"2","author":"Lemal","year":"2013","journal-title":"Leukemia Res Rep"},{"key":"10.1016\/j.clinph.2014.06.031_b0180","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert\u2013Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinph.2014.06.031_b0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0165-5728(94)00183-O","article-title":"Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis","volume":"58","author":"Link","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1749-6632.2012.06772.x","article-title":"SOX1 antibodies in Lambert\u2013Eaton myasthenic syndrome and screening for small cell lung carcinoma","volume":"1275","author":"Lipka","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","article-title":"Favourable prognosis in Lambert\u2013Eaton myasthenic syndrome and small-cell lung carcinoma","volume":"353","author":"Maddison","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinph.2014.06.031_b0200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp.70.2.212","article-title":"Long term outcome in Lambert\u2013Eaton myasthenic syndrome without lung cancer","volume":"70","author":"Maddison","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinph.2014.06.031_b0205","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinph.2014.06.031_b0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0165-5728(96)00152-X","article-title":"Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis","volume":"71","author":"Matusevicius","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0215","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert\u2013Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinph.2014.06.031_b0220","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.clinbiochem.2004.05.007","article-title":"ProGRP: a new biomarker for small cell lung cancer","volume":"37","author":"Molina","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinph.2014.06.031_b0225","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.athoracsur.2009.11.041","article-title":"Thymoma with Lambert\u2013Eaton myasthenic syndrome","volume":"89","author":"Morimoto","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clinph.2014.06.031_b0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0235","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ana.410320419","article-title":"Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma","volume":"32","author":"Mygland","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0240","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","article-title":"Seronegative Lambert\u2013Eaton myasthenic syndrome: study of 110 Japanese patients","volume":"59","author":"Nakao","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0245","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert\u2013Eaton myasthenic syndrome","volume":"34","author":"Newsom-Davis","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0250","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nature03112","article-title":"A synaptic laminin-calcium channel interaction organizes active zones in motor nerve terminals","volume":"432","author":"Nishimune","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.clinph.2014.06.031_b0255","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.59.7.1085","article-title":"Postexercise facilitation of reflexes is not common in Lambert\u2013Eaton myasthenic syndrome","volume":"59","author":"Odabasi","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0260","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0025-6196(12)61144-6","article-title":"Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma","volume":"67","author":"Oguro-Okano","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinph.2014.06.031_b0265","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","article-title":"Electrophysiological diagnostic criteria of Lambert\u2013Eaton myasthenic syndrome","volume":"32","author":"Oh","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2014.06.031_b0270","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/mus.20672","article-title":"Electrophysiological differences in seropositive and seronegative Lambert\u2013Eaton myasthenic syndrome","volume":"35","author":"Oh","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2014.06.031_b0275","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1083\/jcb.200202083","article-title":"Cast: a novel protein of the cytomatrix at the active zone of synapses that forms a ternary complex with RIM1 and munc13-1","volume":"158","author":"Ohtsuka","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clinph.2014.06.031_b0280","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert\u2013Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O\u2019Neill","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.clinph.2014.06.031_b0285","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0290","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2009.09.017","article-title":"Managing non-paraneoplastic Lambert\u2013Eaton myasthenic syndrome: clinical characteristics in 25 German patients","volume":"217","author":"Pellkofer","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0295","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0300","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.410170610","article-title":"Action of Lambert\u2013Eaton myasthenic syndrome IgG at mouse motor nerve terminals","volume":"17","author":"Prior","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0305","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/JTO.0b013e31802f1c9d","article-title":"Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndrome","volume":"2","author":"Pujol","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clinph.2014.06.031_b0310","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/317737a0","article-title":"Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line","volume":"317","author":"Roberts","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.clinph.2014.06.031_b0315","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1 antibodies are markers of paraneoplastic Lambert\u2013Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0320","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0072-9752(07)01509-6","article-title":"The Lambert\u2013Eaton myasthenic syndrome","volume":"91","author":"Sanders","year":"2008","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0325","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0330","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.clinph.2013.11.007","article-title":"Is the decremental pattern in Lambert\u2013Eaton syndrome different from that in myasthenia gravis?","volume":"125","author":"Sanders","year":"2014","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.clinph.2014.06.031_b0335","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.critrevonc.2005.12.001","article-title":"Proteasome inhibitors in lung cancer","volume":"58","author":"Scagliotti","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinph.2014.06.031_b0340","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(89)90893-3","article-title":"Specificity of calcium channel autoantibodies in Lambert\u2013Eaton myasthenic syndrome","volume":"2","author":"Sher","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.clinph.2014.06.031_b0345","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0169-5002(00)00205-1","article-title":"Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC)","volume":"32","author":"Shibayama","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinph.2014.06.031_b0350","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0355","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.humimm.2006.12.005","article-title":"Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib","volume":"68","author":"Subklewe","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0360","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0022-510X(95)00162-U","article-title":"Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert\u2013Eaton myasthenic syndrome","volume":"133","author":"Takamori","year":"1995","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0365","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.48.5.1261","article-title":"Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert\u2013Eaton myasthenic syndrome","volume":"48","author":"Takamori","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0370","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1468-1331.2007.01931.x","article-title":"Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders","volume":"14","author":"Takamori","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0375","doi-asserted-by":"crossref","first-page":"10559","DOI":"10.1523\/JNEUROSCI.4629-12.2013","article-title":"Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert\u2013Eaton myasthenic syndrome","volume":"33","author":"Tarr","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.clinph.2014.06.031_b0380","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mus.880170906","article-title":"Repetitive nerve stimulation studies in the Lambert\u2013Eaton myasthenic syndrome","volume":"17","author":"Tim","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2014.06.031_b0385","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1212\/WNL.54.11.2176","article-title":"Lambert\u2013Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment","volume":"54","author":"Tim","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2014.06.031_b0390","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2008.05.025","article-title":"The Lambert\u2013Eaton myasthenic syndrome 1988\u20132008: a clinical picture in 97 patients","volume":"201\u2013202","author":"Titulaer","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0395","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","article-title":"Screening for small-cell lung cancer: a follow-up study of patients with Lambert\u2013Eaton myasthenic syndrome","volume":"26","author":"Titulaer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinph.2014.06.031_b0400","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","article-title":"SOX antibodies in small-cell lung cancer and Lambert\u2013Eaton myasthenic syndrome: frequency and relation with survival","volume":"27","author":"Titulaer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinph.2014.06.031_b0405","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert\u2013Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinph.2014.06.031_b0410","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: report of an EFNS task force","volume":"18","author":"Titulaer","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0415","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/mus.880140305","article-title":"Single motor end-plates in myasthenia gravis and LEMS at different firing rates","volume":"14","author":"Trontelj","year":"1991","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2014.06.031_b0420","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain\u2013Barre syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0425","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11940-012-0213-6","article-title":"Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, Lambert\u2013Eaton myasthenic syndrome, and neuromyotonia","volume":"15","author":"van Sonderen","year":"2013","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0430","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinph.2014.06.031_b0435","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410420204","article-title":"Effect of Lambert\u2013Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse","volume":"42","author":"Waterman","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0440","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","article-title":"Differences in clinical features between the Lambert\u2013Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases","volume":"104","author":"Wirtz","year":"2002","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clinph.2014.06.031_b0445","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/jnnp.73.6.766","article-title":"Difference in distribution of muscle weakness between myasthenia gravis and the Lambert\u2013Eaton myasthenic syndrome","volume":"73","author":"Wirtz","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinph.2014.06.031_b0450","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert\u2013Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.clinph.2014.06.031_b0455","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2005.04.001","article-title":"P\/Q-type calcium channel antibodies, Lambert\u2013Eaton myasthenic syndrome and survival in small cell lung cancer","volume":"164","author":"Wirtz","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0460","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jneuroim.2004.10.018","article-title":"HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert\u2013Eaton myasthenic syndrome","volume":"159","author":"Wirtz","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clinph.2014.06.031_b0465","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/mus.20332","article-title":"Lambert\u2013Eaton myasthenic syndrome has a more progressive course in patients with lung cancer","volume":"32","author":"Wirtz","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2014.06.031_b0470","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinph.2014.06.031_b0475","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1749-6632.1989.tb24104.x","article-title":"Antibodies against calcium channels in the Lambert\u2013Eaton myasthenic syndrome","volume":"560","author":"Wray","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinph.2014.06.031_b0480","doi-asserted-by":"crossref","first-page":"36453","DOI":"10.1074\/jbc.M109.075523","article-title":"Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit","volume":"284","author":"Wu","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinph.2014.06.031_b0485","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/07357909309024856","article-title":"Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy","volume":"11","author":"Zaheer","year":"1993","journal-title":"Cancer Invest"}],"container-title":["Clinical Neurophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245714003459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245714003459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T11:25:14Z","timestamp":1761391514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388245714003459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":97,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1388245714003459"],"URL":"https:\/\/doi.org\/10.1016\/j.clinph.2014.06.031","relation":{},"ISSN":["1388-2457"],"issn-type":[{"value":"1388-2457","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lambert\u2013Eaton myasthenic syndrome \u2013 Diagnosis, pathogenesis and therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinph.2014.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}